靜脈注射免疫球蛋白市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、地區和競爭格局分類，2021-2031年

全球靜脈注射免疫球蛋白市場預計將從 2025 年的 134.1 億美元成長到 2031 年的 210.1 億美元，複合年成長率為 7.77%。

靜脈注射免疫球蛋白（IVIg）源自數千名健康捐血者的血漿，是治療方法原發性免疫力缺乏缺陷和自體免疫疾病的重要選擇。免疫力缺乏缺陷診斷率的不斷上升以及全球人口老化對免疫調節的需求，進一步鞏固了IVIg的市場基礎。此外，IVIg在神經系統疾病領域的臨床應用不斷拓展，推動了其成長，超越了短期趨勢和近期監管政策的變化。

然而，要確保獲得足夠的血漿原料以滿足日益成長的全球需求，需要建立複雜且高成本的物流系統，這對整個產業構成了重大挑戰。例如，根據澳洲國家血液管理局的報告，在2023-2024會計年度（2024年），澳洲發放了約930萬克免疫球蛋白製劑。這凸顯了供應鏈為滿足消費需求所承受的巨大壓力。因此，快速擴展血漿採集基礎設施的挑戰成為市場進一步成長的主要障礙。

市場促進因素

市場成長的主要促進因素是原發性和續發性免疫力缺乏缺陷疾病診斷數量的增加。隨著醫療系統檢測免疫功能障礙的能力不斷提高，需要終身接受免疫球蛋白替代療法以預防感染疾病的患者群體也不斷擴大。這形成了一個穩定的需求基礎，使得血漿分餾生產者持續擴大產能至關重要。例如，CSL有限公司在其截至2024年8月的會計年度年度報告中指出，其免疫球蛋白產品組合的銷售額成長了20%，達到56.66億美元，凸顯了這些生物療法對已確診患者的重要性。

同時，靜脈注射免疫球蛋白在治療神經系統疾病（尤其是慢性脫髓鞘多發性神經炎，神經病變自體免疫發炎性脫髓鞘性多發性神經病變 (CIDP)）方面的需求不斷成長，顯著擴大了其治療領域。該領域的監管核准正在加速其應用，並加劇對有限血漿資源的競爭。武田藥品工業株式會社於2024年1月發布的新聞稿顯示，III期臨床試驗數據顯示，治療組的復發率僅15.5%，而安慰劑組為31.7%，證實了其療效。這項臨床成功推動了財務成長，Griffols公司2024年生物製藥銷售額達到55.53億歐元的報告便印證了這一點，而這主要得益於免疫球蛋白的強勁應用。

市場挑戰

全球靜脈注射免疫球蛋白（IVIg）市場面臨著許多限制因素，其中之一是取得充足血漿原料需要高度資本密集的物流基礎設施。與採用合成生產的製藥產業不同，IVIg產業受限於人類捐血的生物學局限性以及採集、檢測和運輸所需的龐大基礎設施。這種依賴導致供應鏈僵化，無法快速擴大產能以滿足日益成長的國際自體免疫疾病和免疫力缺乏治療需求，從而有效限制了市場成長。

因此，這種供應瓶頸阻礙了該產業利用診斷率上升所帶來的機會。支援一名患者所需的原料數量龐大，而採集網路卻以難以企及的速度不斷擴張。血漿蛋白治療協會在2024年指出，每年大約需要130份血漿捐贈才能治療一名原發性免疫力缺乏患者。如此巨大的需求凸顯了業務擴張中面臨的重大物流挑戰。隨著臨床需求的成長，該行業難以相應提高其採集能力，這直接影響了產品的供應和整體市場成長。

市場趨勢

市場上的一項關鍵進展是血漿分餾產量的技術最佳化。由於原血漿來源有生物學限制，生產商正積極採用先進的分離技術，以最大限度地提高每次捐血中免疫球蛋白的回收率。這種對營運效率的關注使企業能夠將產量線性成長與血漿採集量線性成長分開，從而實現更穩定的利潤率和更強的供應韌性。例如，2024年2月，Griffols宣布其營運改善計畫已使2023年12月的血漿每公升成本較2022年7月的尖峰時段降低了22%，這充分證明了提高產量技術的經濟效益。

同時，在患者對便利性的需求以及支付方對經濟高效治療環境的需求的推動下，居家靜脈注射免疫球蛋白（IVIg）療法的普及正在迅速推進。這一趨勢正在使治療分散化，從住院機構轉向專業的門診和居家輸液網路，從而實現靈活的治療安排並降低感染風險。這種結構性變化正在推動遠端輸液領域獨立服務提供者的成長。作為這項變更的佐證，Option Care Health在2024年10月發布的報告顯示，其第三季收入淨額達到12.785億美元，年增17.0%，反映出市場對居家及其他場所輸液服務的需求不斷成長。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球靜脈注射免疫球蛋白市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按類型（IgG、IgA、IgM、IgE、IgD）
  • 外用（低丙種球蛋白血症、慢性脫髓鞘多發性神經炎（CIDP）、原發性免疫力缺乏、重症肌無力、多灶性運動神經病變及其他用途）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美靜脈注射免疫球蛋白市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲靜脈注射免疫球蛋白市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區靜脈注射免疫球蛋白市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲靜脈注射免疫球蛋白市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲靜脈注射免疫球蛋白市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球靜脈注射免疫球蛋白市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Bio Products Laboratory Ltd.
• Biotest AG
• China Biologic Products Holdings Inc.
• CSL Behring
• Grifols SA
• Kedrion SpA
• Shanghai RAAS Blood Products Co. Ltd
• Octapharma AG
• Takeda Pharmaceutical Company Limited
• Baxter International Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Intravenous Immunoglobulin Market is projected to expand from USD 13.41 Billion in 2025 to USD 21.01 Billion by 2031, registering a compound annual growth rate of 7.77%. Derived from the pooled plasma of thousands of healthy donors, Intravenous Immunoglobulin (IVIg) serves as a critical treatment for patients suffering from primary immunodeficiency diseases and autoimmune disorders. The market's foundation is strengthened by the increasing prevalence of diagnosed immune deficiencies and an aging global demographic requiring immune modulation. Additionally, the broadening clinical use of IVIg for neurological conditions functions as a fundamental driver of growth, extending beyond temporary trends or immediate regulatory changes.

However, the industry faces substantial hurdles related to the intricate and expensive logistics necessary to secure enough source plasma to satisfy rising global demand. For instance, the National Blood Authority reported that in 2024, approximately 9.3 million grams of immunoglobulin products were issued in Australia during the 2023-24 fiscal year, underscoring the immense strain on supply chains to keep pace with consumption. Consequently, the challenge of rapidly expanding plasma collection infrastructure stands as a major obstacle to further market growth.

Market Driver

The primary catalyst for market growth is the increasing diagnosis of primary and secondary immunodeficiency disorders. As healthcare systems refine their ability to detect compromised immune function, a larger patient population requires lifelong immunoglobulin replacement therapies to prevent infections. This establishes a consistent demand baseline that necessitates continuous capacity expansion by plasma fractionators. For example, CSL Limited reported in their August 2024 Annual Report that immunoglobulin portfolio sales increased by 20% to $5,666 million, highlighting the critical need for these biological treatments among diagnosed patients.

Concurrently, the rising demand for intravenous immunoglobulin in treating neurological conditions, particularly autoimmune neuropathies such as Chronic Inflammatory Demyelinating Polyneuropathy, is significantly expanding the therapeutic landscape. Regulatory endorsements in this area are driving utilization, leading to higher competition for limited plasma resources. According to a January 2024 press release from Takeda, pivotal trial data showed a relapse rate of just 15.5% for patients on therapy compared to 31.7% for the placebo group, confirming its efficacy. This clinical success supports financial growth, as evidenced by Grifols reporting biopharmaceutical revenue of EUR 5,553 million in 2024, driven largely by strong immunoglobulin adoption.

Market Challenge

The Global Intravenous Immunoglobulin Market faces significant constraints due to the sophisticated and capital-intensive logistics needed to obtain adequate volumes of source plasma. Unlike pharmaceutical industries that utilize synthetic manufacturing, the IVIg sector is bound by the biological limitations of human donation and the extensive infrastructure required for collection, testing, and transport. This reliance results in a rigid supply chain where production capabilities cannot be rapidly scaled to meet the increasing international demand for autoimmune and immunodeficiency treatments, effectively limiting market expansion.

As a result, this supply bottleneck hinders the sector's capacity to leverage rising diagnosis rates. The amount of raw material necessary to support a single patient is extensive, placing constant pressure on collection networks to expand at a difficult pace. The Plasma Protein Therapeutics Association noted in 2024 that treating one patient with primary immune deficiency requires about 130 plasma donations per year. This high-volume requirement underscores the significant logistical challenges in scaling operations; as clinical demand rises, the industry finds it difficult to proportionally increase collection capacity, which directly impacts product availability and overall market growth.

Market Trends

A significant evolution in the market is the technological optimization of plasma fractionation yields. Confronted with the biological limitations of sourcing raw plasma, manufacturers are actively deploying advanced fractionation methods to maximize immunoglobulin protein recovery from each donation. This emphasis on operational efficiency enables companies to separate production volumes from the need for linear increases in plasma collection, thereby stabilizing margins and enhancing supply resilience. For instance, Grifols stated in February 2024 that their Operational Improvement Plan led to a 22% reduction in plasma cost per liter by December 2023 compared to the July 2022 peak, illustrating the financial benefits of these yield-improving technologies.

Simultaneously, there is a widespread shift toward the adoption of home-based IVIg infusion therapies, fueled by patient preference for convenience and payer demand for cost-efficient care settings. This trend decentralizes administration, moving treatment from inpatient hospitals to specialized ambulatory and home infusion networks that provide flexible scheduling and lower infection risks. This structural change is driving the growth of independent providers in the remote infusion space. As evidence of this shift, Option Care Health reported in October 2024 that third-quarter net revenue reached $1,278.5 million, a 17.0% increase year-over-year, reflecting the escalating demand for home and alternate site infusion services.

Key Market Players

• Bio Products Laboratory Ltd.
• Biotest AG
• China Biologic Products Holdings Inc.
• CSL Behring
• Grifols SA
• Kedrion SpA
• Shanghai RAAS Blood Products Co. Ltd
• Octapharma AG
• Takeda Pharmaceutical Company Limited
• Baxter International Inc

Report Scope

In this report, the Global Intravenous Immunoglobulin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Intravenous Immunoglobulin Market, By Type

• IgG
• IgA
• IgM
• IgE
• IgD

Intravenous Immunoglobulin Market, By Application

• Hypogammaglobulinemia
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Primary Immunodeficiency Diseases
• Myasthenia Gravis
• Multifocal Motor Neuropathy
• Other Applications

Intravenous Immunoglobulin Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Intravenous Immunoglobulin Market.

Available Customizations:

Global Intravenous Immunoglobulin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Intravenous Immunoglobulin Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (IgG, IgA, IgM, IgE, IgD)
  • 5.2.2. By Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Intravenous Immunoglobulin Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Intravenous Immunoglobulin Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Intravenous Immunoglobulin Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Intravenous Immunoglobulin Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Intravenous Immunoglobulin Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Intravenous Immunoglobulin Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Intravenous Immunoglobulin Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Intravenous Immunoglobulin Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Intravenous Immunoglobulin Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Intravenous Immunoglobulin Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Intravenous Immunoglobulin Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Intravenous Immunoglobulin Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Intravenous Immunoglobulin Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Intravenous Immunoglobulin Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Intravenous Immunoglobulin Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Intravenous Immunoglobulin Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. Middle East & Africa Intravenous Immunoglobulin Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Intravenous Immunoglobulin Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Intravenous Immunoglobulin Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Intravenous Immunoglobulin Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. South America Intravenous Immunoglobulin Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Intravenous Immunoglobulin Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Intravenous Immunoglobulin Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Intravenous Immunoglobulin Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Intravenous Immunoglobulin Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bio Products Laboratory Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Biotest AG
• 15.3. China Biologic Products Holdings Inc.
• 15.4. CSL Behring
• 15.5. Grifols SA
• 15.6. Kedrion SpA
• 15.7. Shanghai RAAS Blood Products Co. Ltd
• 15.8. Octapharma AG
• 15.9. Takeda Pharmaceutical Company Limited
• 15.10. Baxter International Inc

16. Strategic Recommendations

17. About Us & Disclaimer